Tagged with IP,

Saudi Arabia Last year, Dimitri Livadas made the unconventional leap from Big Pharma to a local Saudi firm, Saudi Chemical. In conversation, he explains the motivating factors behind this decision, including Saudi Arabia’s vision for the future, the legacy and growth potential of Saudi Chemical, and the unique opportunity to be part…

Saudi Arabia Farrukh Rehan outlines how GSK Saudi Arabia is actively collaborating with the Saudi government to align its initiatives with Vision 2030 and support national healthcare goals. Through strategic partnerships and MoUs, the company ensures the seamless integration of its innovations into the healthcare system, contributing to improved patient access and…

Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…

Morocco Morocco is currently implementing the most ambitious, far-reaching, and comprehensive health system reorganizations in its history. “What sets this reform apart from all that has happened before is just how starkly it differs in spirit from previous incremental and piecemeal initiatives that have been attempted over the decades,” proudly asserts…

Portugal Speaking from Servier’s new open-plan office in Lisbon, a space aimed at promoting cross-functional integration and “collective intelligence,” experienced industry executive Frédéric Bengold looks back on three successful years at the helm of Servier Portugal and outlines his goals for the future. With a refreshed global visual identity and corporate…

Morocco Recently rebranded from its former name, AMIP, the Moroccan Federation of Pharmaceutical Industry and Innovation (FMIIP) represents the local manufacturers operating in Morocco, which hold a domestic market share of 75 percent. Executive Director Layla Laassel Sentissi highlights some of the key trends in the Moroccan pharma market today, how…

UAE Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years…

Middle East & Africa As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets…

Belgium Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he helped co-found in 1999, Galapagos.   Stoffels is a heavyweight of the global pharmaceutical industry and close ally of the…

USA Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led to a number of breakthrough therapies. Chairman and CEO Bob Bradway recently spoke to the Money Maze podcast about the…

Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos highlights the key learnings from this US experience and…

Belgium With over 140 operating biotech companies representing almost a quarter of Europe’s biotech market and a strong network of universities and research institutes, Belgium boasts a solid biotech ecosystem that continues to thrive despite recent downturns in biotech financing. Beyond more well-known players like Argenx, acquired by Sanofi, and Galapagos,…